


Overall Survival of retrospective 100 cases



Supplementary Figure S1. Overall survival of the 100 cases in pre-crizotinib period. The overall 1-year, 3-year, 5-year and 10-year survival values of the 100 NSCLCs are 91%, 77%, 69% and 36%.